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Abstract
Introduction The experiments reported here address the
question of whether a short-term hormone treatment can
prevent mammary tumorigenesis in two different genetically
engineered mouse models.
Methods Two mouse models, the p53-null mammary epithelial
transplant and the c-neu mouse, were exposed to estrogen and
progesterone for 2 and 3 weeks, respectively, and followed for
development of mammary tumors.
Results In the p53-null mammary transplant model, a 2-week
exposure to estrogen and progesterone during the immediate
post-pubertal stage (2 to 4 weeks after transplantation) of
mammary development decreased mammary tumorigenesis by
70 to 88%. At 45 weeks after transplantation, analysis of whole
mounts of the mammary outgrowths demonstrated the presence
of premalignant hyperplasias in both control and hormone-
treated glands, indicating that the hormone treatment strongly
affects the rate of premalignant progression. One possible
mechanism for the decrease in mammary tumorigenesis may be
an altered proliferation activity as the bromodeoxyuridine
labeling index was decreased by 85% in the mammary glands of
hormone-treated mice. The same short-term exposure
administered to mature mice at a time of premalignant
development also decreased mammary tumorigenesis by 60%.
A role for stroma and/or systemic mediated changes induced by
the short-term hormone (estrogen/progesterone) treatment was
demonstrated by an experiment in which the p53-null mammary
epithelial cells were transplanted into the cleared mammary fat
pads of previously treated mice. In such mice, the tumor-
producing capabilities of the mammary cells were also
decreased by 60% compared with the same cells transplanted
into unexposed mice. In the second set of experiments using the
activated Her-2/neu  transgenic mouse model, short-term
estradiol or estradiol plus progesterone treatment decreased
mammary tumor incidence by 67% and 63%, and tumor
multiplicity by 91% and 88%, respectively. The growth rate of
tumors arising in the hormone-treated activated Her-2/neu mice
was significantly lower than tumors arising in non-hormone
treated mice.
Conclusion Because these experiments were performed in
model systems that mimic many essential elements of human
breast cancer, the results strengthen the rationale for translating
this prevention strategy to humans at high risk for developing
breast cancer.
MMTV = murine-mammary-tumor virus; PCR = PCR; RT = reverse transcriptase.Breast Cancer Research    Vol 9 No 1    Rajkumar et al.
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Introduction
It has long been recognized that hormones have an intimate
and decisive role in the development and progression of mam-
mary tumorigenesis. The earliest treatment for prevention of
breast tumor recurrence in humans (published in 1896) was
removal of the ovaries, the source of the reproductive
hormones estrogen and progesterone [1]. The most effica-
cious treatment for the prevention of recurrence in modern
therapy for breast cancer is treatment with drugs that target
the estrogen pathway, either the estrogen receptor or estro-
gen metabolism [2]. Many risk factors for breast cancer devel-
opment involve the hormonal history of the patient, including
early age of menarche, late age of menopause, late age of first
pregnancy, nulliparity, and estrogen/progesterone hormone
replacement exposure. Indirectly, postmenopausal obesity
and alcohol consumption are thought to enhance breast can-
cer risk through altering estrogen levels [3].
Paradoxically, one of the strongest and extensively docu-
mented protective factors for breast cancer in both humans
and rodent models is short-term stimulation with hormone,
either by means of an early full-term pregnancy or with the hor-
mones estrogen and progesterone. The protective properties
of estrogen and progesterone were initially shown in 1962 by
Charles Huggins [4] and the extensive studies in this area
have been reviewed [5,6]. Studies over the past 30 years to
document and understand the mechanistic basis for this phe-
nomenon have used the traditional rat and mouse chemical-
carcinogen-induced mammary tumor models. These models
use etiological agents that are thought not to be risk factors in
human breast cancer. One of the known risk factors in human
breast cancer is exposure to radiation [7]. Ironically, in the only
study done in the rat where radiation was the initiating agent,
hormones were not protective [8]. These considerations raise
the question of the relevance of the traditional models for
understanding the mechanism of the protective effects of
hormones.
Over the past 10 years, there have been many new mouse
models of mammary cancer based on the enhanced or deleted
expression of specific genes known to have a role in human
breast cancer [9]. One of the best-studied models is deletion
of the p53 gene in BALB/c mammary epithelium [10,11]. In
this model, the deletion of p53 gene expression does not per-
turb the normal growth and differentiation of the mammary epi-
thelium nor its normal dependence on hormones. However,
risk for spontaneous mammary cancer is increased over a 14-
month period, and this risk is enhanced by prolonged stimula-
tion with estrogen and progesterone, by irradiation, or by
chemical carcinogens [10-12]. The cancers that arise in these
mice are locally invasive, exhibit metastases to the lung, and
about 20% retain hormone dependence. In addition, the pre-
malignant phenotype mimics that of human ductal carcinoma
in situ both morphologically and with respect to retaining
estrogen receptor expression [11]. A study of gene expression
profiles of tumors arising in the p53-null mammary epithelium
with a randomly selected group of stage 1 and 2 human breast
cancers found a large number of genes that were commonly
expressed in both sets of tumors [13].
A second and more tumorigenic model is the activated Her-2/
neu (murine-mammary-tumor virus (MMTV)-c-neu) transgenic
mouse model [14,15]. HER-2/neu, an abbreviation for human
epidermal growth factor receptor-2, is a proto-oncogene,
which when activated by mutation or overexpressed has a role
in uncontrolled cancer cell growth. The protein product of the
Her-2/neu  gene is overexpressed in 25 to 30% of human
breast cancers. A significant proportion of human intraductal
breast carcinomas (ductal carcinoma in situ) demonstrate
Her-2/neu amplification/overexpression, suggesting that the
functional activity of this oncogene is enhanced early in the
progression of malignant breast disease. Virgin activated Her-
2/neu transgenic mice have a 100% incidence of mammary
cancer and a high multiplicity of mammary cancers [14,15]. A
full-term pregnancy does not increase the incidence or multi-
plicity of mammary adenocarcinomas in the activated neu
transgenic mice but does decrease the size and metastatic
potential of the mammary tumors in the activated neu trans-
genic mice [16]. As these two models mimic many features of
major subsets of human breast cancer, we tested whether a
short-term exposure to estrogen and progesterone (p53-null
and MMTV-neu models) or just estrogen (MMTV-neu model)
would induce a protective effect on spontaneous
tumorigenesis.
Materials and methods
Mice
BALB/c mice were bred and maintained at Baylor College of
Medicine. The donor mice were BALB/c p53  homozygous
null, and the recipient mice were p53 wild type. FVB (activated
neu) mice were bred and maintained at the Cancer Research
Laboratory, University of California, Berkeley, California, and at
Texas Tech University of Health Sciences Center, El Paso,
Texas. All mice were maintained in conventional mouse facili-
ties with food and water provided ad libitum, and the room
temperature was set at 70°F (21°C). The animal facilities at
Baylor College of Medicine and University of California are
accredited by the American Association of Laboratory Animal
Care. All experiments followed NIH guidelines for th ecare and
use of mice.
p53-null model
The basic transplantation protocol for the experiments using
the p53-null model was as described [10]. In brief, fragments
of mammary ducts from 8 to 10-week-old female p53-null mice
were transplanted into the cleared mammary fat pads of 3-
week-old or 11-week-old female mice. Although the p53 dele-
tion is the same in all donor mice, the array of secondary alter-
ations important for neoplastic development include both
common and unique events. The consequence is that the tum-Available online http://breast-cancer-research.com/content/9/1/R12
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origenic capabilities of mammary gland fragments vary over a
small range between donor mice in the same host environ-
ment. Thus, the time to palpable tumor occurrence in 50% of
animals in any two untreated groups in two different experi-
ments may be different (for example 60 weeks versus 50
weeks). Thus, each experiment always has an untreated con-
trol group for assessment of the effect of a particular treat-
ment. In all the transplantation experiments described here,
three different donors were used for each experiment with
equal representation in the different groups.
In experiment 1 there were two groups of mice. Group 1 com-
prised untreated control mice and group 2 comprised mice
that received Silastic tubing containing 50 μg of estradiol-17β
and 20 mg of progesterone for the period of weeks 2 to 4 after
transplantation. The Silastic tubings were implanted subcuta-
neously dorsally and removed after the 2-week period. Mice
were palpated weekly until 45 weeks after transplantation. At
that time, the mammary fat pads free of palpable tumors were
either collected for the preparation of epithelial cell pellets and
frozen or prepared as whole mounts. This experiment was
repeated identically and designated experiment 1A. Addition-
ally, transplants were collected between weeks 8 and 16 after
transplantation to assess proliferation activity by bromodeoxy-
uridine (BrdU) immunohistochemistry. The mice were injected
intraperitoneally with BrdU 2 hours before tissue collection
and the samples were processed as described previously
[17]. A total of 500 cells were counted from each fat pad
under ×10 magnification. There were four fat pads in each
treatment group. In experiments 1 and 1A, a total of 66 trans-
plants per group were assessed for tumorigenic potential.
Experiment 2 was started 12 months after experiment 1A and
addressed the question of whether the developmental stage of
the mammary epithelium influenced the response to the short-
term hormone exposure. In this experiment there were four
groups of mice. Groups 1 and 2 were identical to the groups
in experiment 1. Thus, epithelial cells were actively proliferating
as the ducts were filling the fat pad. The proliferation index at
this stage was about 8% [11]. Group 3 comprised mice that
received the hormone treatment at 23 to 25 weeks after trans-
plantation at a period when the mammary epithelium had filled
the fat pad and proliferation was in a steady state but tumors
were starting to appear. We included a positive control as
group 4, in which the mice were exposed to a 5 mg pellet of
tamoxifen between weeks 11 and 24. Previous experiments
had shown that lifetime exposure to tamoxifen prevented the
development of mammary tumors in this model system [18].
The mice were palpated weekly until 50 weeks after
transplantation.
Experiment 3 tested whether pretreatment of the recipient
mice with hormones could provide a protective effect on mam-
mary epithelium that had not been directly exposed to the
added hormone exposure. In this experiment there were four
groups of mice. Groups 1 and 2 were as in experiment 1, in
which the duct fragments were transplanted into 3-week-old
mice and estrogen/progesterone was provided at 2 to 4
weeks after transplantation. Groups 3 and 4 contained mice
that received the hormones for 2 weeks in one group (the
other group was untreated age-matched controls), followed by
a rest period of 4 weeks, followed by transplantation of the
duct fragments into the cleared fat pads of 11-week-old mice.
The mice were palpated weekly until 60 weeks after
transplantation.
Whole-mount preparations were made from four mammary
glands from each of the groups in experiments 1 to 3 at 4
weeks after the removal of the Silastic tubing implants. In all
experiments there was no significant difference between the
treated and untreated outgrowths in the percentage of mam-
mary fat pad filled by the implants. All palpable tumors were
fixed in 4% paraformaldehyde for 2 to 4 hours, embedded in
paraffin and processed for staining with hematoxylin/eosin. As
the transplanted mammary epithelium develops primarily mam-
mary adenocarcinomas but also hemangiosarcomas (at 10%
incidence, presumably because of endothelium that is also
transplanted as part of the duct fragment), we assessed all
tumors histologically to confirm the cell type of origin. In the
text throughout, tumor refers to mammary adenocarcinoma.
Mammary adenocarcinoma incidences were evaluated statis-
tically with Fisher's exact test. The BrdU immunohistochemis-
try was performed as described [11].
Activated MMTV-neu model
The design of the experiments using the MMTV-neu model
was slightly different. FVB transgenic mice were treated for 3
weeks, starting at 7 weeks of age, with 100 μg of estradiol in
Silastic capsules. Another set of transgenic animals were
treated with 100 μg of estradiol and 15 mg of progesterone,
also in Silastic capsules. The doses of estradiol used result in
pregnancy levels of estradiol in the circulation [19]. The con-
trol animals received empty Silastic capsules for the same
duration. Mice were palpated once every week for 8 months to
monitor for mammary cancer development. Histopathological
examination was performed to confirm the carcinomatous
nature of the palpable tumors. Mammary cancer incidence
was evaluated statistically with the χ2 test.
Hormone preparations
All mice received either empty Silastic tubing or the hormones
in Silastic tubing. For both the p53-null model and the neu
model, the tubings were prepared with the same protocol. The
hormones were packed in individual Silastic capsules (Dow
Corning; size 0.078 inch (2 mm) internal diameter, 0.125 inch
(3.2 mm) outside diameter, 2 cm in length). Estradiol-17β
(Sigma, St Louis, MO, USA) was packed in the Silastic cap-
sules in a cellulose matrix. Progesterone (15 mg; Sigma) was
packed into the Silastic capsules also in a cellulose matrix. All
these capsules were primed by soaking overnight in mediumBreast Cancer Research    Vol 9 No 1    Rajkumar et al.
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199 (Gibco, Grand Island, NY, USA) at 37°C. Silastic cap-
sules were implanted subcutaneously dorsally.
RNA analysis
A group (n = 3) of control animals and animals treated with
estradiol or estradiol plus progesterone were killed immedi-
ately after the 3 weeks of hormone treatments. Mammary
glands were removed from all the groups for the transgene
expression analysis. Another set of animals (n = 15) received
the above-mentioned hormone treatments and were killed at 9
months of age. Mammary tumor and mammary tissue adjacent
to the mammary tumors were excised, snap-frozen in liquid
nitrogen, and stored at -80°C for molecular analysis. Total
RNA isolated from the normal mammary gland, mammary
tumor, and mammary tissue adjacent to the mammary tumor
was subjected to real-time RT-PCR analyses to study the
expression of the transgene [20]. RNA was isolated with Trizol
reagent, and real-time reverse transcription was performed
with the one-step QuantiTect SYBR Green kit (Qiagen Inc.,
Valencia, CA, USA) in accordance with the manufacturer's
specifications. 18S RNA was used as standard and positive
control in these assays. Fold changes between samples for
relative Her-2/neu transgene mRNA expression were calcu-
lated from the differences in ΔCt values between the two sam-
ples (ΔΔCt) and the equation Fold change = 2-ΔΔCt. Real-time
RT-PCR was performed with the oligonucleotide primers 5'-
GGAACCTTACTTCTGTGGTGT-3' and 5'-GGAAAGTC-
CTTGGGGTCTTCT-3' targeting the SV40 poly(A) region of
the transgene. Cyclin D1 expression was performed on the
mammary tumors from the control and hormone-treated
groups with the oligonucleotide primers 5'-CATCAAGTGT-
GACCCGGACTG-3' and 5'-CCTCCTCCTCAGT-
GGCCTTG-3'.
Results
Effect of short-term hormone stimulation on p53-null 
mammary tumorigenesis
The tumorigenic response of the p53-null mammary epithelium
exposed to estrogen and progesterone combination at 2 to 4
weeks after transplantation is shown in Figure 1 and Table 1.
In the control transplants, 16/66 (24%) produced tumors by
45 weeks after transplantation, with an initial tumor latency of
20 weeks. This incidence is consistent with previous studies
[10,18]. In the hormone-treated mice, only 2/66 (3%) pro-
duced tumors (p < 0.05). This experiment demonstrates con-
clusively that a short-term hormone treatment can delay tumor
development in a non-carcinogen model of mammary cancer.
Whole-mount analysis of the glands in experiments 1 and 1A
at 4 weeks and at 8 to 12 weeks after transplantation did not
indicate a significant difference in outgrowth morphology. The
outgrowths exhibited normal alveolar differentiation to 2 weeks
of estrogen/progesterone exposure at 4 weeks after trans-
plantation. At 8 to 12 weeks after transplantation, the out-
growths appeared as normal mammary duct arborization with
no evidence of ductal hyperplasia (Figure 2). However, whole-
mount analysis of the glands at 45 weeks after transplantation
revealed extensive ductal hyperplasia in both control and hor-
mone-treated glands. Premalignant lesions were present in
13/31 glands in the estrogen/progesterone-treated group
(42%) and 6/13 glands in the untreated controls (46%) (Fig-
ure 2; p > 0.05). These data suggest that hormones act to
block premalignant progression and not the onset of hyper-
plastic growth.
Effect of developmental state on tumorigenesis in p53-
null mammary epithelium
The tumorigenic response of the mammary epithelium
exposed to estrogen and progesterone combination at 23 to
25 weeks after transplantation is shown in Figure 3 and Table
1. In the control transplants, 10/20 (50%) produced tumors by
48 weeks after transplantation, with an initial tumor latency of
24 weeks. In the transplants exposed to hormone combination
when they were actively filling the fat pad, the tumor incidence
was 3/20 (15%), with an initial tumor latency of 44 weeks. In
contrast, the transplants exposed to the hormone combination
much later after transplantation had an initial tumor latency
equivalent to the controls, but the final tumor incidence (4/20;
20%) was not significantly different (p > 0.05) from that in the
group exposed to hormones early after transplantation. The
transplants exposed to tamoxifen for only 3 months did not
develop any tumors after 50 weeks. This experiment demon-
strates that a short-term treatment administered at either the
actively proliferating or the steady-state stage of mammary
development can delay tumorigenesis.
Figure 1
Effect of short-term hormone treatment on tumorigenesis in p53-null  mammary epithelial transplants Effect of short-term hormone treatment on tumorigenesis in p53-null 
mammary epithelial transplants. The data are the sum of two identical 
experiments (experiments 1 and 1A). Mice treated with estradiol and 
progesterone had a significant decrease in tumor incidence (p < 0.05). 
Filled circles, untreated; open circles, hormone-treated. The flow dia-
gram illustrates the experimental treatment plan. C, clear mammary 
gland; T, transplant; E, estrogen; P, progesterone.Available online http://breast-cancer-research.com/content/9/1/R12
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Effect of hormone pretreatment of the host on 
tumorigenesis in p53-null mammary epithelium
The tumorigenic capability of the p53-null mammary epithelial
cells either directly exposed to estrogen/progesterone or just
to the estrogen/progesterone-treated host is shown in Figure
4 and Table 1. The tumorigenic capability was the same
whether the target epithelial cells were directly exposed to
estrogen/progesterone or transplanted into an estrogen/pro-
gesterone-treated host environment (3/15 versus 4/20,
respectively;  p  > 0.05). The tumorigenic response was
decreased from 45% (18/40 combined controls) to 20% (7/
35 combined treatment; p < 0.05).
The proliferative state of the mammary epithelial cells was
assessed at 4 to 12 weeks after removal of the hormones in all
three experiments (Figures 5 and 6). In experiment 1, at 4 and
8 weeks after hormone removal, the control transplants
showed a BrdU-labeling index of 9.8 and 8.2, respectively, in
comparison with 1.5 and 1.8, respectively, in the hormone-
treated transplants (p < 0.05). In experiment 2, at 4 weeks
after hormone removal (that is, 26 weeks after transplantation),
the control transplants showed a BrdU-labeling index of 19.8
in comparison with 7.8 in the hormone-treated transplants (p
< 0.05). In experiment 3, at 12 weeks after hormone removal
(that is, 8 weeks after transplantation into 11-week-old mice),
the control transplants had a BrdU-labeling index of 9.5 in
comparison with 4.5 in the transplants in the hormone-treated
mice (p < 0.05).
Effect of hormone treatment on MMTV-neu mammary 
tumorigenesis
The marked response of the p53-null mammary epithelium to
a short-term exposure to hormone raised the question of
whether a similar response would occur in a more tumorigenic
model of mammary tumorigenesis. The MMTV-activated neu
model provided such a model, because tumors develop rapidly
and with high multiplicity. The effect of either short-term treat-
ment with estradiol or estradiol plus progesterone on mam-
mary carcinogenesis was tested. The data in Figure 7 and
Table 1 indicate that both treatments were equally effective in
providing protection. Mammary cancer incidence after treat-
ment with estradiol alone (33%) or with estradiol plus proges-
terone (37%) was significantly decreased in comparison with
the controls (100%).
All the control mice developed mammary cancers by 5 months
of host age with a multiplicity of 6.8 cancers per mouse. Treat-
ment with estradiol (0.6 cancers per mouse) or estradiol plus
progesterone (0.8 cancers per mouse) drastically reduced
mammary cancer multiplicity and also approximately doubled
the mammary cancer latency (Figures 8 and 9). This experi-
ment was repeated once with identical results. A second
repeat experiment was not informative because the control
untreated mice did not develop tumors with their usual early
latency of 13 to 15 weeks of host age but started to develop
tumors only at 30 weeks.
Mice were examined twice weekly beginning after the hor-
mone treatments, and the earliest tumors were detectable by
Table 1
Tumorigenesis in short-term hormone-treated mice
Experiment Group Tumors/transplants (percentage) Percentage inhibition Experiment duration (weeks)
1/1A Untreated 16/66 (24) - 45
E/P (5–7) 2/66 (03)a 87.5 45
2 Untreated 10/20 (50) - 48
E/P (5–7) 3/20 (15)a 70 48
E/P (23–25) 4/20 (20)a 60 48
Tamoxifen (11–24) 0/20 (0)a 100 48
3 Untreated, trans. (3) 9/20 (45) - 58
E/P (5–7), trans. (3) 3/15 (20)a 56 58
Untreated, trans. (11) 9/20 (45) - 58
E+P (5–7), trans. (11) 4/20 (20)a 56 58
4 Untreated 15/15b (100) 24
E/P 6/15b (37) a 63 32
E5 / 1 5 b (33) a 67 32
E, estrogen; P, progesterone; trans., transplantation. ap < 0.05; bin this experiment, the column refers to the number of tumor-bearing mice/total 
number of mice.Breast Cancer Research    Vol 9 No 1    Rajkumar et al.
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palpation (Figure 9). The sizes of tumors were recorded after
each examination. In control mice the average age at which
palpable tumors were first detected was 95 days. Tumors
were initially palpated 142 days in estradiol-treated mice and
at 138 days in mice treated with estradiol plus progesterone.
Tumor growth was monitored until the tumor in each mouse
had reached a diameter of 1 cm. The difference in tumor
growth rate between the control and hormone-treated mice
was significant. There was almost a threefold difference in the
time required for the mammary tumors to grow to 1 cm in
diameter (after initial palpation) in mice treated with estradiol
or estradiol plus progesterone compared with the controls.
Real-time PCR analyses demonstrated that expression of the
transgene was not significantly altered by the transgene in the
normal mammary tissue, mammary tumors and the mammary
tissue adjacent to the mammary tumor. There was a significant
difference in the expression levels of cyclin D1 (Figure 10).
Mammary tumors from the control group had a significantly
higher (about 5.6-fold) expression of cyclin D1 in comparison
with animals treated with estradiol alone or estradiol plus
progesterone.
Discussion
The experiments reported here are the first to address the
question of whether short-term hormone treatment can delay
tumorigenesis in genetically engineered models of mammary
cancer. All previous experiments, with one exception in which
radiation was used, were performed in rodent models treated
with chemical carcinogen. The results show clearly that a
Figure 2
Effect of short-term hormone treatment on gland morphology in p53-null transplants Effect of short-term hormone treatment on gland morphology in p53-null transplants. (a,b) Mammary whole mounts were prepared 4 weeks after the 
removal of hormones in mice from experiment 1A. The ductal organization at the histological and microscopic (hematoxylin/eosin-stained sections, 
not shown) was similar in the untreated (a) and treated (b) mice (original magnification ×2). (c–f) Whole mounts were prepared at 45 weeks after 
transplantation in transplants that had not yet developed palpable tumors. A large number of transplants in the untreated group (46%) (original mag-
nifications ×1 (c) and ×2 (d)) and in the treated group (42%) (original magnifications ×1 (e) and ×2 (f)) contained areas of ductal hyperplasias 
(arrows).Available online http://breast-cancer-research.com/content/9/1/R12
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short-term hormone treatment of estrogen with or without pro-
gesterone can significantly delay tumorigenesis in two differ-
ent genetically engineered mouse models. The models differ in
fundamental mechanisms of mammary tumorigenesis. The
p53-null epithelium is a model in which a major tumor
suppressor gene is deleted and aneuploidy is a major feature
of the mammary tumors. The tumors arise over a 14-month
period and the incidence reaches only 50 to 60% during this
period. In contrast, the activated-neu model represents the
overexpression of an oncogene, and tumors arise very rapidly
and with high multiplicity. These results need to be repeated
with other genetically engineered mouse models, such as the
BRCA1  and c-myc  models, to determine the wider
applicability of this effect of hormones. Conceptually, this
result is important because the genetically engineered models
replicate more faithfully basic features of human breast cancer
than do the chemical carcinogen models.
Several results are of general interest. In the p53-null model,
the mature gland as well as the developing (that is, immedi-
ately post-pubescent) gland was responsive to the protective
state induced by the hormone treatment. This result implies
that there is no unique developmental state of susceptibility. In
the MMTV-activated neu model, the effect of hormones was
tested on the developing mammary gland at 7 to 10 weeks of
age. These results suggest that the translation of this
Figure 3
The effect of duration of hormone exposure on tumorigenesis in p53- null mammary epithelial transplants The effect of duration of hormone exposure on tumorigenesis in p53-
null mammary epithelial transplants. The effect of hormone exposure 
was compared with that of a hormone receptor antagonist, tamoxifen. 
Mice treated with estradiol and progesterone, either early or late, or 
treated with tamoxifen, had a significant decrease in tumor incidence (p 
< 0.05). Filled circles and solid line, control; filled circles and dotted 
line, early hormone exposure; inverted triangles and broken line, late 
hormone exposure; upright triangle, tamoxifen. The flow diagram illus-
trates the experimental treatment plan.
Figure 4
The effect of hormone-induced systemic changes on tumorigenesis in  p53-null mammary epithelial transplants The effect of hormone-induced systemic changes on tumorigenesis in 
p53-null mammary epithelial transplants. Mammary epithelial trans-
plants in a host exposed to estradiol and progesterone before trans-
plantation (open triangles and dot-dashed line) also had a significant 
decrease in tumor incidence (p < 0.05) compared with mice not 
exposed to the hormones (filled triangles and broken line). The flow dia-
grams illustrate the experimental treatment plans.
Figure 5
Bromodeoxyuridine-labeling index (number labeled per 500 cells) in  hormone-treated p53-null mammary epithelial transplants Bromodeoxyuridine-labeling index (number labeled per 500 cells) in 
hormone-treated p53-null mammary epithelial transplants. Transplants 
from each experiment (1, 2 and 3) were assayed for bromodeoxyurid-
ine. The black bars represent untreated transplants, the gray bars hor-
mone-treated transplants. The number above each pair of bars 
indicates the number of weeks after the removal of hormones. In exper-
iment 3, 12 weeks after the removal of hormone represents 8 weeks 
after transplantation. There were four transplants per treatment group. 
Five hundred cells were counted in each transplant. All four compari-
sons were significantly different (p < 0.05).Breast Cancer Research    Vol 9 No 1    Rajkumar et al.
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approach to humans is not limited to the young post-pubes-
cent female but can be applied to the young to middle-aged
adult female. Although the emphasis from the human epidemi-
ology studies has always been on early first pregnancy as a
critical determinant for protection, the use of a specific hor-
mone combination for short durations might be applicable to a
wider age range than previously thought. This conclusion is in
line with experiments in the rat model that show a protective
effect of hormones even after initiation by a chemical
carcinogen. Huggins and colleagues originally reported that
estradiol and progesterone given for 30 days, beginning 15
days after carcinogen administration, inhibited the appearance
of mammary cancers in rats treated with chemical carcinogens
[4]. We also demonstrated that protection against mammary
carcinogenesis could be achieved by treatment with physio-
logical levels of estradiol and progesterone for 21 days or less
[21,22]. In the MMTV-activated neu model, 100 μg of estradiol
in the Silastic tubing yielded a circulating level of serum estra-
diol of 98.56 ± 8.37 pg/ml (SEM) (n = 6) at 21 days after
implantation of the tubing. The groups treated with estradiol
plus progesterone yielded similar results (L Rajkumar, unpub-
lished data).
In support of the idea that the mature gland is responsive to
the protective effects of a short-term exposure to estrogen and
progesterone is the observation that this hormone combina-
tion seems to be acting to delay premalignant progression.
Figure 6
Immunohistochemistry of bromodeoxyuridine-labeled mammary epithelial cells Immunohistochemistry of bromodeoxyuridine-labeled mammary epithelial cells. The brown nuclei (arrows) represent the uptake of bromodeoxyurid-
ine into cells undergoing DNA synthesis. (a) Untreated; (b) treated with estrogen plus progesterone.
Figure 7
Effect of short-term hormone treatment on mammary carcinogenesis in  the activated Her-2/neu transgenic mice Effect of short-term hormone treatment on mammary carcinogenesis in 
the activated Her-2/neu transgenic mice. Mice treated with estradiol 
alone (7/21) or estradiol plus progesterone (9/24) had a significant 
decrease in the incidence of mammary tumors compared with the con-
trols (20/20) at 8 to 9 months of age (p < 0.01).
Figure 8
Effect of short-term hormone treatment on mammary cancer multiplicity  in the activated Her-2/neu transgenic mice Effect of short-term hormone treatment on mammary cancer multiplicity 
in the activated Her-2/neu transgenic mice. The group of mice (n = 21) 
treated with estradiol alone developed a total of 13 mammary tumors 
and the group of mice (n = 24) treated with estradiol plus progesterone 
developed a total of 20 mammary tumors by 8 to 9 months of age; in 
comparison, the group of control mice (n = 20) developed a total of 
136 mammary tumors (p < 0.005). Results are expressed as means ± 
SEM.Available online http://breast-cancer-research.com/content/9/1/R12
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The presence of frequent hyperplasia in the hormone-treated
gland but the absence of invasive cancers supports this con-
clusion. There is some limited information in the literature that
supports this idea. Reddi and colleagues have presented data
that show the presence of microtumors in the glands of hor-
mone-treated rats under conditions in which the controls had
a high incidence of invasive cancers [23]. The data presented
in the present study would be the first demonstration of this
result in mice. Experiments that test the growth potential of
these microtumors or hyperplasias by transplantation into con-
trol animals have yet to be reported. It is evident that there is a
point in premalignant progression at which the cells are no
longer susceptible to the preventive effects of this hormone
combination. Examination of the tumor incidence curves of
mice that were exposed to hormones at 23 to 25 weeks of age
clearly show that the first tumors appeared with a latency
similar to that in control mice. Thereafter, this group behaved
similarly to the mice that received the early exposure to
hormone.
One of the cellular mechanisms underlying the protective
effect involves a diminution of the proliferative potential of the
mammary cells. All experiments in the p53-null model demon-
strated that the proliferative index of the hormone-treated cells
was reduced by 53% to 85% of that of untreated control mam-
mary cells at the steady-state level observed in the mature
gland. Interestingly, the ability of the short-term hormone treat-
ment to stimulate proliferation and differentiation during the
expansion period at 2 to 6 weeks after transplantation was not
compromised, because the extent of filling of the fat pad was
the same in the two groups at 6 weeks after transplantation.
This suggests that the mechanism for controlling proliferation
in the two states (that is, expanding versus a steady-state cell
population) might be different either at the level of the cell type
that is proliferating in the two states or at the molecular level.
We have not yet evaluated the proliferative indices of the
hyperplasias in the control and hormone-treated mice because
the original observations that determined the presence of
these hyperplasias in the hormone-treated mice were
performed on whole mounts of the glands, and, indeed, the
result was surprising to us. However, in the MMTV-activated
neu  model, the decrease in proliferative activity was also
observed in the tumors arising in the hormone-treated mice.
This decrease was manifested at the cellular level in a
decrease in cyclin D1 expression.
Perhaps the most surprising result is the apparent systemic
effect of the hormones. This experiment demonstrated conclu-
sively that the effect of the hormones can be mediated, in part,
by changes induced at the systemic level and/or the mammary
stroma. This idea was presented by Thordarson and col-
leagues in studies on the carcinogen-induced rat mammary
system [24]. Attempts to test this hypothesis were only partly
successful [25]. The results presented here demonstrate con-
clusively that hormone-induced effects at the systemic level
and/or at the mammary stroma can affect tumorigenesis in the
p53-null mammary cells. Such an effect is not without prece-
dent. Barcellos-Hoff and Ravani demonstrated that irradiated
stroma can alter premalignant progression of a mouse mam-
mary outgrowth line, COMMA-D [26]. Maffini and colleagues
showed that stroma treated with a chemical carcinogen (N-
methyl-N-nitrosourea) can enhance the progression of rat
mammary cells to mammary tumors [27]. Schedin and col-
leagues [28] demonstrated that the extracellular matrix of
mammary stroma from different reproductive states alters
mammary epithelial morphogenesis as well as mammary epi-
Figure 9
Effect of short-term hormone treatment on tumor growth rate in the acti- vated Her-2/neu transgenic mice Effect of short-term hormone treatment on tumor growth rate in the acti-
vated Her-2/neu transgenic mice. Treatment with estradiol alone or 
estradiol plus progesterone significantly increased the time taken for 
the mammary tumors to grow from initial palpation to a diameter of 1 
cm in comparison with the controls. Results are expressed as means ± 
SEM.
Figure 10
Cyclin D1 mRNA expression levels in mammary tumors arising in acti- vated Her-2/neu mice Cyclin D1 mRNA expression levels in mammary tumors arising in acti-
vated Her-2/neu mice. There was an approximately sixfold increase in 
the level of cyclin D1 in mammary tumors arising in control mice in com-
parison with tumors arising in hormone-treated mice. Results are 
expressed as means ± SEM.Breast Cancer Research    Vol 9 No 1    Rajkumar et al.
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thelial growth rate. Specifically, they showed that matrix iso-
lated from parous stroma delayed glandular morphogenesis.
The cellular and molecular mechanisms underlying the
changes systemically or at the mammary stroma are beginning
to be identified. Alterations in both transforming growth factor-
β signaling [26] and growth hormone signaling [23,24] have
been implicated. Interestingly, we could not demonstrate
altered systemic insulin-like growth factor-1 levels in our hor-
mone-treated mice at 4 weeks after hormone removal (D
Medina and A Lee, unpublished data).
Finally, it is apparent that the preventive activity can be
induced by a modest dose of estrogen alone (100 μg) or a
combined dose of estrogen and progesterone. Previously we
had shown that short-term sustained exposure to 100 μg of
estradiol resulted in pregnancy levels of estradiol in circulation
[19,29]. We further showed that a pregnancy level of estradiol
alone or a combination of estradiol and progesterone was
highly effective in inducing refractoriness to chemical carcino-
gen-induced rat mammary carcinogenesis. Similarly to the pro-
tection observed in rats by a pregnancy level of estradiol,
activated Her-2/neu mice are also rendered refractory to mam-
mary cancer development by short-term hormone treatments.
These studies illustrate two of the major paradoxes of the role
of hormones in mammary tumorigenesis. On the one hand, a
short duration of estrogen and progesterone or estrogen alone
imparts a protective effect on tumor development. On the
other hand, continuing the same dose of hormones for a pro-
longed period strongly stimulates the development of tumors
in this same system as well as in other mouse models
[5,18,30]. This same result has been reported in the rat mam-
mary tumor system [31]. Different mechanisms underlying the
protective effects have been proposed by several
investigators. Sivaraman and colleagues and Ginger and
colleagues [21,32,33] emphasize the induction of a different
developmental fate as a consequence of hormone exposure.
Thordarson and colleagues have argued for a systemic effect
involving the downregulation of pituitary hormones [24,34,35].
In either event, one would have to conclude that continuing
exposure to hormones overrides these mechanisms. Mecha-
nistically, the basis for this override is not clear.
The second paradox is that by either exposing the mammary
gland to a short duration of hormones or blocking the same
hormone pathway (for example by exposure to tamoxifen) a
similar result is generated, namely a decrease in tumorigenic
potential. However, the cellular pathways perturbed by the two
treatments might be entirely different because tamoxifen-
treated outgrowths do not show the presence of hyperplasias
that occur in the hormone-treated outgrowths.
In summary, these studies provide a further rationale for con-
sidering the use of short-term hormone exposure as a preven-
tive modality, particularly in high-risk individuals. Despite the
extensive documentation of the preventive potential of early
full-term pregnancy and its mimicry by estrogen and progester-
one, there is great resistance to the use of these hormones as
a preventive modality. In part, the resistance is due to the over-
whelming data showing that prolonged exposure to estradiol
and progesterone increases the risk for breast cancer [36].
This resistance might be mitigated by recent data indicating
that hormone replacement therapy with estrogen alone does
not increase the risk for breast cancer [37]. Perhaps this
resistance will be overcome once the mechanisms underlying
the preventive effects of specific hormone combinations and
duration of exposure are understood.
Conclusion
These studies demonstrate that short doses of the hormones
estrogen and progesterone induce a long-lasting protective
effect on mammary tumorigenesis in two genetically engi-
neered mouse models. At least part of the effects of the hor-
mone treatment is mediated through systemic and/or
mammary stroma alterations.
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